

Immunotherapy of Melanoma: Facts and Hopes

Sarah A. Weiss¹, Jedd D. Wolchok², and Mario Sznol¹



Abstract

Melanoma is among the most sensitive of malignancies to immune modulation. Although multiple trials conducted over decades with vaccines, cytokines, and cell therapies demonstrated meaningful responses in a small subset of patients with metastatic disease, a true increase in overall survival (OS) within a randomized phase III trial was not observed until the development of anti-CTLA-4 (ipilimumab). Further improvements in OS for metastatic disease were observed with the anti-PD-1-based therapies (nivolumab, pembrolizumab) as single agents or combined with ipilimumab. A lower bound for expected 5-year survival for metastatic melanoma is currently approximately 35% and could be as high as 50% for the nivolumab/ipilimumab combination among patients who would meet

criteria for clinical trials. Moreover, a substantial fraction of long-term survivors will likely remain progression-free without continued treatment. The hope and major challenge for the future is to understand the immunobiology of tumors with primary or acquired resistance to anti-PD-1 or anti-PD-1/anti-CTLA-4 and to develop effective immune therapies tailored to individual patient subsets not achieving long-term clinical benefit. Additional goals include optimal integration of immune therapy with nonimmune therapies, the development and validation of predictive biomarkers in the metastatic setting, improved prognostic and predictive biomarkers for the adjuvant setting, understanding mechanisms of and decreasing toxicity, and optimizing the duration of therapy.

Introduction

Incidence rates of melanoma have doubled over the past 30 years due to an aging population, increased ultraviolet (UV) sunlight exposure, ongoing tanning bed use, and improved awareness and detection (1). Although melanoma represents only 1% of all skin cancers diagnosed, it is by far the most fatal with an estimated 10,000 deaths in the United States in 2018 (2). Because of UV light exposure and possibly the biology of melanin, the DNA of melanoma cells in most patients contains a relatively large number of mutations (3). The mutations result in altered protein sequences, a subset of which is processed and presented as "foreign" peptides on surface MHC molecules and therefore recognized by a host T-cell response. Melanosomal proteins such as MART-1, gp100, and tyrosinase can also be recognized by host T-cell responses, possibly because of molecular mimicry between the peptides presented on cell surface MHC molecules and peptides from pathogen-associated proteins (4). In addition, melanomas often reexpress developmental proteins such as the cancer-testes antigens, which can be recognized by host immune responses (5). Multiple studies have shown that T lymphocytes can be grown *ex vivo* from tumor-infiltrating lymphocytes (TIL) of metastatic melanoma lesions, and in most patients, a subset of these TIL specifically recognize autologous melanoma. Consistent with the latter observations, clinical activity was observed with a variety of local or systemically administered immune therapies including IL2 (6), IFN α (7, 8), and adoptive cell therapy

(ACT; refs. 9–11). Objective response rates (ORR) in metastatic melanoma ranged from approximately 15% for cytokines to up to 50% for ACT with expanded TIL, but only 5%–20% of patients achieved long-term complete responses (CR). Nevertheless, the durable CRs provided proof of concept for immunotherapy efficacy in melanoma and supported further development of novel immune modulators in melanoma and other malignancies.

Subsequent development of mAbs targeting the immune checkpoints cytotoxic T-lymphocyte antigen-4 (CTLA-4; ipilimumab, approved by the FDA in 2011) and programmed death 1 (PD-1; nivolumab, pembrolizumab, approved by the FDA in 2014) drastically transformed the management of advanced melanoma and of melanoma at high risk for distant recurrence after resection of the primary and regional nodal disease (Table 1). Average life expectancy for a patient with metastatic melanoma ranged from six to twelve months before introduction of the immune checkpoint inhibitors (ICI); 3-year overall survival (OS) rates in clinical trials of anti-PD-1 alone or in combination with ipilimumab now exceed 50% (12). Five-year survival rates for anti-PD-1 alone could approach 35%–40% (13), and the 4-year survival rate for nivolumab plus ipilimumab exceeded 50% (14). Although not well documented in the current trials, our substantial institutional experiences with these agents indicate that a large fraction of the 5-year survivors are off treatment and have no active disease, having required only the immune therapies and in some cases additional radiation or surgical resection of residual oligometastatic disease.

However, despite the substantial advances, roughly half of all patients with melanoma treated with ICIs will demonstrate primary or acquired resistance (15, 16). No highly accurate predictive biomarkers exist and there are limited effective treatment options available once resistance develops, except for targeted BRAF + MEK inhibitors in tumors expressing driver mutations in the *BRAF* gene. While adverse effects from immune therapies (irAE) are manageable in most patients, they cause significant morbidity in a subset and may require treatment discontinuation.

¹Yale University School of Medicine, New Haven, Connecticut. ²Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.

Corresponding Author: Sarah A. Weiss, Yale University School of Medicine, Yale Cancer Center, 333 Cedar Street, PO Box 208032, New Haven, CT 06520. Phone: 203-737-2572; Fax: 203-785-3788; E-mail: sarah.a.weiss@yale.edu

Clin Cancer Res 2019;25:5191–201

doi: 10.1158/1078-0432.CCR-18-1550

©2019 American Association for Cancer Research.

Table 1. Practice-changing trials for immune checkpoint inhibitors in locally advanced and metastatic melanoma

Drug	Trial	Phase	Population	Treatment arms	Primary outcome	(95% CI)	HR	P
Unresectable/metastatic ipi (FDA approved 2011)	Hodi and colleagues (2010; ref. 24)	III	Unresectable stage III/IV previously treated	ipi 3mg/kg × 4 + gp100 vaccine	Median OS (months)	10 (8.5–11.5)	0.68 (vs. gp100)	<0.001
	Robert and colleagues (2014, KEYNOTE-001; ref. 121)	I	ipi refractory	gp100 vaccine Pembrolizumab 2 mg/kg q3wk Pembrolizumab 10 mg/kg q3wk	ORR (%)	10.1 (8–13.8) 6.4 (5.5–8.7) 26 (-) 26 (-)	0.66 (vs. gp100)	0.003
	Ribas and colleagues (2015, KEYNOTE-002; ref. 122)	II	ipi refractory	Pembrolizumab 2 mg/kg q3wk Pembrolizumab 10 mg/kg q3wk Investigators' choice chemo	Median PFS (months)	2.9 (2.8–3.8) 2.9 (2.8–4.7) 2.7 (2.5–2.8)	0.57 (vs. chemo) 0.5 (vs. chemo)	<0.0001 <0.0001
	Schachter and colleagues (2017, KEYNOTE-006; ref. 36)	III	Unresectable stage III/IV up to 1 prior treatment (excluding anti-CTLA-4, PD-1/PD-L1 agents)	Pembrolizumab 10 mg/kg q2wk Pembrolizumab 10 mg/kg q3wk ipi 3 mg/kg q3wk × 4	12-month OS rate (%)	74.1 (-) 68.4 (-) 58.2 (-)	0.63 (vs. ipi) 0.69 (vs. ipi)	0.0005 0.0036
	Weber and colleagues (2015, CheckMate-037; ref. 123)	III	Unresectable or metastatic progression on ipi and BRAF inhibitor if BRAF mutant	Nivolumab 3 mg/kg q2wk Investigators' choice chemo	ORR (%)	31.7 (23.5–40.8) 10.6 (3.5–23.1)	—	—
	Robert and colleagues (2015, CheckMate-066; ref. 124)	III	Metastatic previously untreated BRAF-WT	Nivolumab 3 mg/kg q2wk Dacarbazine 1000 mg/m ² q3wk	1-year OS rate (%)	72.9 (65.5–78.9) 42.1 (33–50.9)	0.42	0.001
	Wolchok and colleagues (2013; ref. 23)	I	Unresectable stage III/IV previous therapy with T-cell-modulating Abs (excluding ipi for pts in the sequenced-regimen cohorts)	Nivolumab 0.3 mg/kg + ipi 3 mg/kg Nivolumab 1 mg/kg + ipi 3 mg/kg Nivolumab 3 mg/kg + ipi 1 mg/kg Nivolumab 3 mg/kg + ipi 3 mg/kg	ORR (%)	21 (5–51) 53 (28–77) 40 (16–68) 50 (12–88) 40 (27–55)	—	—
	Postow and colleagues (2015, CheckMate-069; ref. 125)	II	Unresectable stage III/IV treatment naive	All ipi 3 mg/kg + nivolumab 1 mg/kg × 4 followed by nivolumab 3 mg/kg q2wk ipi 3 mg/kg + placebo × 4 followed by placebo q2wk	ORR (%) BRAF-WT BRAF mutant BRAF-WT	61 (49–72) 52 (31–73) 11 (3–25) 10 (0–45)	—	—
	Larkin and colleagues (2015, CheckMate-067; ref. 16)	III	Unresectable stage III/IV treatment naive	Nivolumab 3 mg/kg q2wk + placebo Nivolumab 1 mg/kg + ipi 3 mg/kg × 4 followed by nivolumab 3 mg/kg q2wk	Median PFS (months)	6.9 (4.3–9.5) 11.5 (8.9–16.7)	0.57 (vs. ipi) 0.42 (vs. ipi)	<0.001 <0.001
	Wolchok and colleagues (2017, CheckMate-067; ref. 12)	III	Unresectable stage III/IV treatment naive	ipi 3 mg/kg q3wk × 4 + placebo Nivolumab 3 mg/kg q2wk up to 1 year ipi 10 mg/kg q3wk × 4, then q12 wk up to 1 year	3-year OS (months); 3-year OS rate (%)	2.9 (2.8–3.4) 37.6 (52, 29.1–NR) NR (58; 38.2–NR)	—	—
Adjuvant	Weber and colleagues (2017, CheckMate-238; ref. 59)	III	Resected stages IIIB–IV (AJCC 7th ed.)	Nivolumab 3 mg/kg q2wk up to 1 year ipi 10 mg/kg q3wk × 4, then q12 wk up to 1 year	1-year RFS rate (%)	70.5% (66.1–74.5) 60.8% (56–65.2)	0.65	<0.001
	Eggermont and colleagues (2018, ref. 60)	III	Resected stages IIIA (<1 mm micrometastasis)-IIIC (AJCC 7th ed.) completion lymphadenectomy required	Placebo up to 1 year Pembrolizumab 200 mg i.v. q3wk up to 1 year	1-year RFS rate (%)	75.4% (71.3–78.9) 61% (56.5–65.1)	0.57	<0.001
	NCT03068455 (CheckMate-915)	III	Resected stage IIIB–IV (AJCC 8th ed.)	Nivolumab 240 mg q2wk + ipi 1 mg/kg q6wk + placebo Nivolumab 480 mg q4wk + placebo ipi 10 mg/kg q3wk × 4, then q12wk (this arm was subsequently removed)	RFS	Results not yet available	—	—
	Abbreviations: AJCC, American Joint Committee on Cancer; CI, confidence interval; ipi, ipilimumab; NR, not reached; OS, overall survival; PFS, progression-free survival; pts, patients; q, every; RFS, recurrence-free survival; wks, weeks; WT, wild type.							

Finally, ICIs are expensive agents with important individual and societal economic implications, problems that must be addressed with more refined dosing schedules, optimization of treatment duration, and rational patient selection in the future (17, 18).

ICIs in Melanoma

Before 2011, standard-of-care immune therapy for melanoma was limited to IFN α for primary/regional disease at high risk for recurrence and high dose IL2 for advanced/metastatic disease. High dose IL2 produced ORRs of up to 16% and a CR rate of 6%, based on data obtained before ICIs moved to first-line treatment of melanoma (19). No randomized trials of high dose IL2 versus chemotherapy were conducted. Recognition that T-cell activation through the T-cell receptor (TCR) was modulated by ligand-receptor costimulatory and coinhibitory signals provided additional targets for immune intervention. CD28 was the first costimulatory molecule identified in 1986 and binds to CD80/CD86 expressed on APCs, but can be countered by induced cell surface expression of CTLA-4, which competitively binds to CD80/CD86 with higher affinity than CD28 (20). PD-1 is another coinhibitory receptor induced by T-cell activation and has two known ligands, PD-L1 and PD-L2 (21). PD-L1, also known as B7-H1, was found on the cell surface of melanoma cells, on other immune cells within the tumor microenvironment, and on dendritic cells. Multiple other T-cell costimulatory and coinhibitory ligand-receptor interactions have been discovered (22). The immunobiology of these pathways is complex, could influence various immune cell subsets including regulatory T cells, and may have roles in naïve T-cell priming as well as in expansion and function of effector T cells in the tumor microenvironment. Blocking mAbs against both CTLA-4 and PD-1 were shown to produce clinical activity that surpassed any of the prior available therapies and revolutionized the care of patients with melanoma (23). A major challenge for improving therapy is to fully understand the baseline host antitumor immune response and posttherapy evolution of the response that results in antitumor activity.

Anti-CTLA-4

Ipilimumab and tremelimumab ORRs are in the same range as high-dose IL2, and responses can also be quite durable (24, 25). Several important lessons were learned during anti-CTLA-4 development, including management of the induced irAEs, and the varying patterns of response kinetics, for example, the observation of clear clinical disease progression of existing and new lesions in the first 6–12 weeks of treatment followed in some cases by dramatic disease regression, or pseudoprogression, which occurs in an estimated 10% of patients (26, 27). Growing experience with anti-CTLA-4 demonstrated that the standard radiographic RECIST may underestimate clinical benefit from ICIs. Since then and with development of anti-PD-1, multiple iterations of modified RECIST and immune-related response criteria for patients receiving ICIs have been developed, however RECIST is still the most common criteria in use (28–32). There have also recently been reports of rapid progression, termed hyperprogression, in some patients treated with checkpoint blockade (29, 30, 33). Further study of this important area is needed to better understand underlying biology.

Anti-CTLA-4 was active in patients who had progressed on prior IL2. Ipilimumab improved median OS compared with a gp100 peptide vaccine (10 vs. 6.4 months) in previously treated

patients with advanced melanoma and was the first ICI to be approved by the FDA for any malignancy in 2011 (24). Follow-up revealed a 3-year OS of 22% and a plateau of the survival curve for up to 10 years, consistent with the observation of durable responses (34). Although a randomized study showed ipilimumab 10 mg/kg produced superior survival to the approved 3 mg/kg (median 15.7 vs. 11.5 months; ref. 35), the outcomes are still inferior to studies of single-agent anti-PD-1 (nivolumab and pembrolizumab; ref. 36).

Anti-PD-1

Both nivolumab and pembrolizumab are superior to ipilimumab based on single-agent trials and randomized studies (16, 36). When comparing results for similar groups of patients, nivolumab and pembrolizumab produce nearly identical rates of adverse events, objective response, progression-free survival (PFS) and OS. In one trial, single-agent pembrolizumab demonstrated superior PFS and 2-year OS rates (55% vs. 43%, cross-over was allowed) compared with ipilimumab (36). Three- and 4-year survival rates for pembrolizumab and nivolumab in previously untreated patients are 51% (37) and 42% (38). Five-year survival for pembrolizumab in treatment-naïve patients is 41% (13). Five-year survival for nivolumab in previously treated patients was estimated at 35% (39). Both pembrolizumab and nivolumab produce much lower rates of irAEs than ipilimumab, although types of irAEs are similar. PD-1 inhibition became the standard-of-care first-line therapy for metastatic melanoma after FDA approval in 2014 (36). Of note, patients with or without tumor PD-L1 expression receive survival benefit from anti-PD-1 compared with a noneffective treatment such as dacarbazine (37). Anti-PD-1 has also shown clinical benefit for several specific melanoma subgroups, for example, in patients with desmoplastic melanoma, a rare histologic variant with a high mutation burden (40), and for untreated brain metastases in which pembrolizumab yielded a brain metastasis response rate of 26% and 2-year OS of 48% (41).

Combinations of anti-PD-1 and anti-CTLA-4

In CheckMate-067 that compared combination ipilimumab and nivolumab or nivolumab to ipilimumab alone, the combination demonstrated 3- and 4-year OS rates of 58% and 53%, compared with 52% and 46% for nivolumab and 34% and 30% for ipilimumab (12, 14). The combination produced substantially greater rates of toxicity than single-agent nivolumab, although manageable and reversible in almost all patients. Nearly 40% of patients discontinued treatment in the combination arm. Outcome in those experiencing severe toxicity and requiring steroids or other agents to reverse toxicity was not compromised (42). On the basis of, in part, improvement in ORR and PFS in the *post hoc* comparison of the combination to nivolumab, the combination was approved by the FDA in 2015 (12, 16). Of note, patients experiencing toxicity from the combination were not allowed to receive nivolumab alone after resolution of toxicity, which may have negatively affected the OS in that arm.

In subsequent single-arm studies and a small randomized phase II trial, a lower dose of ipilimumab (1 mg/kg) was combined with the more standard single-agent dose of either nivolumab or pembrolizumab, resulting in lower rates of severe toxicity (43) and activity appears similar. For example, a phase Ib trial of pembrolizumab 2 mg/kg combined with low-dose ipilimumab (1 mg/kg) reported an ORR of 61% (44). The effects

of the altered dose ratios on PFS and OS can only be accurately assessed in larger randomized trials, but based on current data, differences would likely be small and therefore only detectable in very large trials. CheckMate-064 assessed whether sequential administration of ipilimumab followed by nivolumab or the reverse sequence could decrease toxicity and maintain similar efficacy to combined ipilimumab and nivolumab. Treatment-related adverse events (AE) were similar between the two study arms. Patients in the nivolumab followed by ipilimumab group had higher response rates at week 25 (41% vs. 20%) and improved 12-month OS rates (76% vs. 54%) compared with the ipilimumab followed by nivolumab group (45). Ipilimumab alone and ipilimumab plus anti-PD-1 have shown activity in patients unresponsive to or with acquired resistance after single-agent anti-PD-1 (46, 47). Current data cannot exclude the possibility that sequential anti-PD-1 followed by ipilimumab alone or ipilimumab/anti-PD-1 combination could produce similar survival to the combination therapy given first-line.

Both clinical and laboratory features have been assessed to identify the subset of patients that clearly benefit from the addition of ipilimumab to anti-PD-1. In Checkmate-067, PFS and OS were improved by the combination in the subset with PD-L1-negative tumors (at the <5% level in stratification, or at the <1% level in *post hoc* analysis) but the difference was not statistically significant. Exploratory analyses using time-dependent receiver-operating characteristic curves also determined that PD-L1 expression could not reliably predict OS (14).

Melanoma brain metastases, a common occurrence and therapeutic challenge, are typically treated with local therapy such as stereotactic radiosurgery. There is now evidence for use of ICI that appears to provide benefit in a subset of patients with asymptomatic, small, untreated brain metastases. In a single-arm phase II study, the combination of ipilimumab/nivolumab demonstrated significant activity against baseline untreated brain metastases (similar to activity against non-CNS metastases; ref. 48), and in a similar brain metastases population, the combination appeared superior when randomized against anti-PD-1 alone, although sample size was very small (49). The results of a small randomized study in the stage III neoadjuvant setting also suggested superior results for ipilimumab/nivolumab over nivolumab alone (50). In certain populations, such as metastatic disease from mucosal primaries, retrospective analyses show that the combination is superior to nivolumab alone, but the advantage occurs in the group with PD-L1-negative tumors (which represents most of the patients; ref. 51). Development of effective immunotherapeutic approaches for metastatic uveal melanoma also remains a challenge and most clinical trials exclude this population due to its distinct tumor biology (52). Only a small subset of patients with uveal melanoma responds to ipilimumab (53) or anti-PD-1 (54), and data are not yet available on the activity of ipilimumab plus nivolumab. An integrative analysis of uveal melanomas from the Cancer Genome Atlas suggests that an inflammatory molecular subgroup does exist, but patient selection is still an issue (55). Extrapolating from clinical data to date, combination ipilimumab and nivolumab may represent a preferred first-line therapy for patients with PD-L1-negative tumors, elevated LDH, mucosal primaries, and/or untreated brain metastases.

Cross-study comparisons suggest an advantage in median and OS for first-line anti-PD-1-based therapy over BRAF/MEK inhibitors in melanoma harboring a BRAF V600 mutation. However,

for certain disease presentations in which very rapid clinical response is required or immune therapies are contraindicated, targeted molecular therapies should be given first (56). This question is being formally addressed by an ongoing phase III trial randomizing patients with BRAF V600-mutant melanoma to targeted therapy with dabrafenib and trametinib followed by ipilimumab and nivolumab at time of disease progression, or vice versa (NCT02224781).

Adjuvant immunotherapy

Prior to development of ICIs, the majority of patients with completely resected melanoma at high risk for recurrence could be offered adjuvant IFN α or pegylated -IFN; however, the agents were associated with bothersome and chronic adverse effects during therapy and only provided modest recurrence-free survival (RFS) benefit and a small OS advantage (57). A randomized trial of ipilimumab at 10 mg/kg versus placebo for completely resected stage III melanoma improved RFS and OS; however, it caused a high rate of grade 3 and 4 AEs (54%; ref. 58). Adjuvant anti-PD-1 quickly replaced ipilimumab in 2017 after CheckMate-238 showed improved 12-month RFS rates for nivolumab compared with ipilimumab (70.5% vs. 60.8%), with lower rates of high grade toxicity (14.4% vs. 45.9%) in patients with resected stage IIIB, IIIC, or IV melanoma. The HR for disease recurrence or death was 0.65; however, survival results have not yet been reported (59). Pembrolizumab also improved RFS compared with placebo (60). In the latter trial, effects on OS are eagerly awaited because all placebo patients were offered pembrolizumab at time of recurrence, which could address the value of treatment in the adjuvant setting versus waiting to treat until disease recurrence. Accrual to Checkmate-915 (NCT03068455) was recently completed in which nivolumab plus low-dose ipilimumab was compared with nivolumab monotherapy in patients with completely resected stage IIIB/C/D or stage IV melanoma. Patients with stage IIIA-IIIC [American Joint Committee on Cancer (AJCC) VII] resected melanoma whose tumors contain a BRAF V600 mutation are also eligible to receive dabrafenib plus trametinib, which was FDA approved in 2018 for use in the adjuvant setting (61); however, targeted therapies have not been compared with ICIs in the adjuvant setting.

Other Immunotherapies for Metastatic Melanoma

In looking forward for approaches to improve therapeutic outcomes, reviewing past development efforts of other immune modulators is instructive. Because of its presumed immunogenicity, most immune modulators were tested initially in metastatic melanoma. Using objective response as the measure of clinical activity, most agents were either inactive or at best demonstrated low response rates. Immune modulators tested in clinical trials included cancer vaccines, cytokines, costimulatory receptor agonists, and multiple types of cell therapies.

Many types of cancer vaccines progressed to clinical development, immunizing against shared melanosomal proteins or cancer-testes antigens, or against antigens contained in autologous tumor or allogeneic tumor cells. Multiple antigen delivery approaches and immunologic adjuvants were employed in the vaccine trials, including gene-modified cells, peptides or proteins

with adjuvant, antigen loaded onto autologous dendritic cells, and delivery of defined antigens by viral vectors or DNA plasmids (62). Rare responses of small-volume distant metastatic disease were observed in some of these trials. Vaccine development is currently focused on immunization against autologous neoantigens defined by whole-exome sequencing or RNAseq combined with bioinformatics analyses to predict binding of peptide sequences containing the mutation to the patient's HLA molecules (63, 64). All older vaccine trials in the adjuvant setting have failed to improve RFS or OS.

Intratumoral immunization efforts began with substances such as BCG and progressed over time to include cytokines delivered by various means, oncolytic viruses, Toll-like receptor (TLR) agonists, and STING agonists. A replicating herpesvirus containing GM-CSF, T-VEC, or talimogene laherparepvec, was approved by the FDA in 2015 for intratumoral administration after demonstrating modest ORR compared with GM-CSF (26% vs. 6%) in a phase III trial for patients with unresected stage IIIB–IV melanoma (65). Most responses occurred in injected lesions and regional noninjected disease, with rare responses in distant noninjected small-volume disease (66). T-VEC has also been studied in a phase II trial in combination with ipilimumab compared with ipilimumab alone (ORR 39% vs. 18%) and in a phase III trial of pembrolizumab plus T-VEC versus pembrolizumab alone, which is ongoing (NCT02263508; ref. 67).

In addition to IL2 and IFN α , many cytokines were also tested including type II IFNs, IL4, IL6, IL12, IL18, and IL21, FLT-3 ligand, and M-CSF. Pegylated IL10 and several forms of IL15 are currently in clinical trials (68). Although several of the cytokines produced low rates of objective responses, development as single agents has not yet proceeded beyond phase II (69, 70).

T-cell costimulatory antibodies targeting CD-137 (4-1BB), OX40, ICOS, and GITR have entered the clinic. Low rates of response were observed with urelumab (CD137 agonist antibody), but doses higher than 0.1 mg/kg were associated with liver toxicity (71). Phase II studies of other agents have not been reported. Notably, a phase I trial of agonist anti-CD40 produced objective responses in 4 of 15 (27%) on an intermittent dosing schedule but was inactive when given weekly (72), and until recently, was not pursued further as a single agent for melanoma.

Predictive biomarkers are not available for any of the above-cited agents, and it remains possible that several could be active in subsets of patients with disease progression after exposure to anti-PD-1 \pm anti-CTLA-4. Many of the agents were also developed before anti-PD-1 or anti-CTLA-4 were available. Preclinical studies indicate that several of the agents when combined with anti-CTLA-4 or anti-PD-1 (or both) could address mechanisms of resistance to ICIs in subsets of patients. Anti-CTLA-4 may be important to allow optimal expansion and broadening of T-cell responses following immunization, and release of inhibitory effects on T cells by anti-PD-1 may optimize the antitumor effect of tumor antigen-specific T cells induced, expanded, and driven to the tumor microenvironment by other agents. Although most combination studies include a PD-1/PD-L1 antagonist, it is important to emphasize that meaningful antitumor activity has been observed in melanoma with high-dose IL2, anti-CTLA-4, and TIL ACT, suggesting that alternate combinations or approaches may drive T-cell activation to a threshold beyond sensitivity to PD-1 pathway inhibition.

Mechanisms of Response and Nonresponse to PD-1 Pathway Antagonists

Approximately 50% of all patients with advanced melanoma presenting for treatment will demonstrate primary or acquired resistance to anti-PD-1–based therapies (12, 36). At the time of presentation, melanoma metastases have coevolved with the antimelanoma immune response for long periods, possibly many years. The immune response to tumor is shaped by the tumor but also by host genetic factors and environmental factors such as prior pathogen exposures and the microbiome. The immune response itself is complex and involves the interaction of many types of immune cells, many molecular interactions between the cells, and includes stimulatory and inhibitory signals and actions. It is within this complex and heterogeneous host–tumor immune relationship that physicians apply relatively narrow therapeutic interventions in the hope of altering the threshold for productive antitumor immune reaction. Given the relatively limited access to human tissue at baseline and after an intervention, and the technological limitations in measuring the many variables simultaneously, critical mechanisms for response and nonresponse are difficult to define, particularly for individual patients.

Studies of pretreatment tumor biopsies suggest that potential biomarkers of melanomas most responsive to anti-PD-1–based immunotherapy include increased CD8 T-cell infiltration (73), an IFN γ gene signature, or expression of PD-L1 on tumor cells or immune cells (74). While these biomarkers are challenging to incorporate into meaningful clinical practice at this time, new biomarkers are in development. The type of CD8 T cell within tumors may be important, for example, those expressing markers of earlier differentiation such as CD28 or the TCF7 transcription factor (75). The correlation of tumor mutation burden with response for melanoma is logical but there are outliers in terms of precise association and the features of mutation encoded neoantigens leading to functional immune responses are not clearly established (76–78). Lack of response has been associated with a specific transcriptional signature associated with epithelial-to-mesenchymal transition, myeloid cells, and angiogenic factors such as VEGF. Several factors outside of the tumor microenvironment appear to influence anti-PD-1 response including species of bacteria within the gut microbiome (79, 80), and various circulating protein classes such as complement, the acute phase response, and wound healing (81). Viewed another way, the mechanisms responsible for lack of response to anti-PD-1–based therapies may be grouped into several categories: lack of prior priming of naïve T cells to produce tumor antigen-specific T cells; exclusion of T cells from the tumor; lack of supportive cytokines or costimulation within the tumor; T-cell suppression caused by coinhibitory ligand-receptor interaction, by cytokines and other soluble ligands for inhibitory receptors on T cells, by suppressive myeloid cells or regulatory T cells (Tregs), or by adverse metabolic conditions such as low oxygen or glucose; and loss of tumor recognition by T cells, for example, downregulation of surface MHC molecules, antigen processing and presentation defects, or simply loss of antigen expression. Because of the many possible mechanisms, biomarkers should be prospectively incorporated into future clinical trials and validated to ultimately guide treatment for individual patients. Single-agent therapies are unlikely to address resistance alone due to the high degree of tumor heterogeneity and the complexity of the host immune–tumor

relationship. Therefore, most development has focused on combination therapies.

Combination Immunotherapy Strategies

Many combination trials are in progress or are in development, most combining with anti-PD-1 or anti-PD-L1 and a smaller number in combination with anti-CTLA-4. Targeted, chemotherapeutic, antiangiogenic, and immunotherapeutic agents have all been combined with standard ICIs. Trials have been developed for previously untreated patients, or for patients with primary or acquired resistance. In the context of single-arm phase II trials conducted in patients without prior exposure to either agent in the combination, activity is often compared with historical controls receiving the "standard" agent, either anti-PD-1 or anti-CTLA-4. Interpretation of data from the phase II trials can be confounded by unknown biases in patient selection. Caution is warranted when concluding that a combination is superior or inferior to single-agent therapy from uncontrolled phase II trials, although the results of these studies are used to proceed to and design the larger confirmatory randomized trials. Activity signals are possibly more reliable for combinations studied in acquired or primary resistance to anti-PD-1 or to anti-PD-1/anti-CTLA-4, but even in this setting low rates of late response or pseudoprogression from prior therapy, or the potential for reresponse when disease progresses after an interval off-treatment, can lead to an overestimation of the combination partner's activity (82, 83). Attention to pharmacodynamic or mechanistic activity of the combinatorial partner can be very informative, even if additional clinical activity is not observed (84). It is important to consider this point before abandoning a novel combination approach, which may be enhanced with additional agents or alterations in dosing.

Although it is outside the scope of this review to describe all the ongoing combinations, several approaches to address potential major mechanisms of nonresponse to anti-PD-1 or anti-PD-1/anti-CTLA-4 combination are illustrative of broader efforts. The approaches include blockade of other coinhibitory ligand-receptor pathways, blockade of various other T-cell-inhibitory mechanisms in the tumor microenvironment, modulation of inhibitory immune cells, delivery of key proliferative or other agonist signals to T cells, and approaches to increase or broaden the antigen-specific T-cell response including immunization or ACT.

LAG-3

Lymphocyte activation gene-3 (LAG-3) is a T-cell-associated inhibitory checkpoint molecule coexpressed with PD-1 that regulates immune tolerance and T-cell homeostasis. Preclinical studies have demonstrated that dual PD-1 and LAG-3 blockade synergistically stimulate T-cell responses and decrease tumor burden more than either agent alone (85–87). LAG-3 was the third inhibitory receptor, after CTLA-4 and PD-1, to be targeted with mAbs in clinic trials starting in 2013 and multiple LAG-3 inhibitors are now in development (BMS-986016, LAG525, and MK-4280; ref. 88).

A phase I/II trial studying anti-LAG-3 (BMS-986016) 80 mg plus nivolumab (NCT01968109) in patients with advanced melanoma whose disease progressed on anti-PD-1/PD-L1 demonstrated ORR of 11.5% [1 CR, 6 partial responses (PR)]. ORR was 3.5-fold higher in patients whose tumors had greater than or equal to 1% positivity for LAG-3 expression, compared with those who

were LAG-3 negative (ORR 18% vs. 5%) but was unrelated to PD-L1 status. Treatment was well tolerated, with only a 4% rate of grade 3 or 4 treatment-related AEs (89). On the basis of this data, a phase II/III study of relatlimab (BMS-986016) plus nivolumab versus nivolumab alone is now recruiting treatment-naïve patients with advanced melanoma (NCT03470922).

IDO

Indoleamine 2,3-dioxygenase 1 (IDO1) is an IFN-inducible enzyme that catabolizes tryptophan and promotes tumor-mediated immunosuppression. IDO1 is overexpressed in cancers including melanoma and inhibition of IDO1 is thought to shift the tumor microenvironment from a tumor-promoting inflammatory state to one of immune stimulation (90). The selective IDO1 inhibitor epacadostat was combined with pembrolizumab in the phase I/II ECHO-202/KEYNOTE-037 study in multiple tumor types including treatment-naïve patients with advanced melanoma (91).

As of October 2017, ORR for 50 patients enrolled on the phase II study was 62% (9 CR, 22 PR) with responses observed in both PD-L1-positive and -negative patients (ORR 70% vs. 56%). Twelve-month PFS and OS rates were 63% and 92%, respectively, and treatment was well tolerated (92). These promising results of similar efficacy to dual ICIs with lower toxicity led to the Phase III ECHO-301/KEYNOTE-252 study in which 706 treatment-naïve patients with advanced melanoma were randomized 1:1 to pembrolizumab combined with either epacadostat or matched placebo. Unexpectedly, there were no differences between the epacadostat and placebo arms for ORR (34% vs. 31%) or 12-month PFS (37% for both) (93). This disappointing data resulted in cancellation and/or downsizing of multiple clinical trials studying IDO inhibition in melanoma, although more work is needed to identify the specific subset of patients that may respond due to specific dependence on the IDO pathway for escape from immune surveillance.

CSF-1R and CD40

Immunotherapies including CSF1R inhibitors (CSF1Ri) and CD40 agonists (CD40 α) target innate immune cells such as macrophages. Preclinical studies have supported the hypothesis that tumor-associated macrophages may confer resistance to ICIs (94). Macrophage colony-stimulating factor 1 (CSF-1) is chemotactic signal that stimulates monocyte tumor infiltration and macrophage differentiation (95, 96). Increased CSF-1 and CSF1R expression has been associated with a poor prognosis (97). CD40 is expressed on macrophages and other antigen-presenting cells (APC) and binds to CD40L on T cells. CD40 agonists increase the tumoricidal activity of macrophages and stimulate maturation of APCs. In a poorly immunogenic melanoma mouse model, combination CSF1Ri and CD40 α suppressed tumor growth more than either agent alone and did so in a T-cell-independent fashion (98). A phase I/II trial (NCT03502330) is currently studying the safety and efficacy of the CSF1Ri cabiralizumab combined with the CD40 α APX005M with or without nivolumab in patients with advanced melanoma, renal cell carcinoma, or non-small-cell lung cancer whose disease has progressed on anti-PD-1/PD-L1.

4-1BB

4-1BB (CD137/TNFSF9) is a costimulatory receptor and member of the TNF receptor family that is expressed on both innate and

adaptive immune cells (99). 4-1BB agonism promotes CD8⁺ T-cell proliferation, enhances TCR signaling, and induces immunologic memory (100, 101). Therapeutic approaches combining a 4-1BB agonist with and without ICIs have been established in preclinical models (101, 102). A phase I dose-escalation study of BMS-663513 (anti-4-1BB, urelumab) in advanced solid malignancies enrolled 83 patients of whom 54 had melanoma and demonstrated clinical activity including 3 PRs in patients with melanoma (103). However, the follow-up phase II study of second-line BMS-663513 for melanoma was terminated early due to an increased incidence of grade 4 hepatitis. This resulted in withdrawal of several other trials that planned to study 4-1BB agonists at that time (100), but retrospective analyses revealed that hepatic toxicity was dose related, and trials of urelumab were reinitiated at a dose of 0.1 mg/kg (71). Data from preclinical models have suggested that irAEs are significantly reduced when 4-1BB agonists are combined with ICIs (104). A phase I/II trial combining urelumab and nivolumab in patients with advanced melanoma reported a 50% ORR [Society for Immunotherapy of Cancer (SITC) 2016] and several studies are planned or currently recruiting that are studying combinations of 4-1BB with other immunomodulatory approaches.

NKTR-214

NKTR-214 is a CD122 agonist and prodrug composed of IL2 conjugated to 6 releasable polyethylene glycol (PEG) chains that increases T-cell and NK-cell proliferation and enhances PD-1 expression. In melanoma mouse models, NKTR-214 increased antitumor efficacy and decreased toxicity compared with aldesleukin (105). NKTR-214 monotherapy demonstrated minimal clinical activity in a phase I/II trial but led to PIVOT-02, a phase I/II trial of NKTR-214 and nivolumab in patients with locally advanced or metastatic tumors including melanoma (NCT02983045). As of May 2018, ORR was 50% for the immunotherapy-naïve melanoma cohort in the stage II portion of the trial. ORR for PD-L1-negative and -positive patients was 42% and 62%, respectively. Eighty-percent of patients had a normal LDH, one-third had liver metastases, and disease stage in most patients was M1b or M1c. Data from PIVOT-02 for patients with immunotherapy-refractory melanoma is not yet available. PIVOT-02 is also now recruiting patients treated with NKTR-214 in combination with nivolumab and ipilimumab. Randomized trials are planned and will be necessary to determine the contribution of NKTR-214 to the baseline effect of anti-PD-1.

TLR agonists

TLR stimulation can enhance antigen presentation and stimulate immune activation (106). ILLUMINATE-204 is a phase II study (NCT02644967) of the TLR-9 agonist IMO-2125 administered intratumorally in combination with ipilimumab or pembrolizumab in patients with PD-1 refractory advanced melanoma. A preliminary ORR of 47% in 15 evaluable patients merits further evaluation and accrual is ongoing (107). A phase III trial of IMO-2125 plus ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma (ILLUMINATE-301) is also currently recruiting patients (NCT03445533).

In the same refractory population, CMP-001, a CpG-A oligodeoxynucleotide and TLR9 agonist, is being studied by intratumoral injection in combination with pembrolizumab in a phase Ib trial (108). Preliminary data show ORR of 40% with tumor reduction occurring in both injected and noninjected lesions, with

most responses lasting over 6 months. These studies suggest that intratumoral injection of TLR9 agonists, and possibly other agents such as oncolytic viruses or STING agonists, could induce antigen presentation and systemic T-cell responses in patients whose tumors have little or no baseline immune infiltrate.

ACT

Given the high rate of activity of the ICIs as first-line therapies, and the clinical and technical challenges of ACT, current studies of ACT are primarily focused on patients resistant or nontolerant to the ICIs. For TIL ACT, clinical responses are limited by the quality and quantity of tumor-resident antigen-specific T cells, and after *ex vivo* expansion, their ability to reach and infiltrate the tumor and subsequently overcome immunosuppressive factors in the tumor microenvironment (109). In a phase II trial (NCT02360579), 9 ICI-resistant patients treated with ACT had ORR of 33% after an albeit short median follow-up of 3.6 months (110) and the trial is ongoing. In a separate single-institution study, 74 patients treated with ACT had ORR of 43%. When responses were grouped on the basis of prior treatment, ORR was 51% in treatment-naïve patients and 33% in patients who received prior ipilimumab, who also had decreased OS post-ACT (24.6 vs. 7.7 months). There were not enough patients to analyze impact of prior anti-PD-1 monotherapy on outcomes (111). In the first trial of TIL produced by shipment to and from a central facility, ORR was 38% among 47 patients, most of whom had received prior anti-PD-1 alone or in combination with ipilimumab (112). Activity of TIL in this setting is encouraging and provides the foundation for future approaches that combine with ICIs or improve cell properties through genetic engineering such as with TCR-engineered T cells targeting differentiation and cancer-testes antigens (113).

Targeted agents

Of note, ICIs are also being studied in combination with inhibitors of the MAPK pathway (NCT02027961, NCT02967692, NCT02908672, NCT03273153). Controversy exists over the impact of adding MAPK pathway inhibitors to ICIs. While several preclinical studies initially reported that MAPK inhibitors can positively modulate the immune microenvironment (114), more recent data have demonstrated that PD-1-resistant melanomas have a transcriptional signature consistent with innate anti-PD-1 resistance (IPRES), defined as having upregulation of genes modulating mesenchymal transition, cell adhesion, angiogenesis, and extracellular matrix remodeling. This IPRES signature is very similar to that induced by combined BRAF/MEK or BRAF inhibition, suggesting that these drugs may mediate resistance to anti-PD-1 (81). The phase II KEYNOTE-022 study randomized patients with BRAF-mutant melanoma to dabrafenib and trametinib plus pembrolizumab or placebo. The primary outcome of PFS was 16 months for the pembrolizumab arm and 10.3 months for the placebo arm (HR 0.66), but this outcome did not reach significance for the prespecified HR goal. In addition, the triplet combination was more toxic with 58% of patients experiencing grade 3–5 adverse events (115).

There is also evidence that MEK inhibition alone may improve T-cell function and enhance antigen presentation and thereby may improve the effect of anti-PD-1/PD-L1 therapies (116). Using this rationale, a phase Ib trial reported ORR of 45% for combined atezolizumab and cobimetinib in patients with BRAF-mutant and wild-type advanced melanoma (117). Ultimately,

optimal dosing and complex sequencing issues for ICIs and MAPK inhibitors will need to be addressed in future studies.

Future Directions and Conclusions

The ultimate goal of immunotherapy treatment in patients with advanced melanoma is to eradicate the disease and/or produce long-term durable responses. Given the complexity of the anti-tumor immune response, combination rather than single-agent strategies will likely dominate the investigational trial landscape.

For those who respond to ICIs, optimal duration of treatment is unknown but is crucial to understand from quality of life, toxicity, and health economics perspectives. Multiple studies suggest that a limited rather than indefinite course of ICIs may be sufficient to provide meaningful durable responses (12). For example, 90% of patients who developed a CR on pembrolizumab remained disease-free after a 2-year median follow-up from drug discontinuation (118). This can be true even for patients who do not develop a CR. In KEYNOTE-006, after median 9-month follow-up of patients who completed pembrolizumab treatment, PFS rates were 95%, 91%, and 83% in patients with a CR, PR, and SD (119). It is highly encouraging that even those patients without a CR who discontinue ICIs can be free of disease progression. Besides clinical implications, length of treatment raises broader economic concerns. Drug costs alone for 6 months of anti-PD-1 can reach \$145,000 per patient, costs rise steeply with dual ICIs and subsequent toxicity management, and this will become financially unsustainable as more patients with many different malignancies have access to ICIs (17, 18).

For those patients who develop resistance to ICIs, new combinatorial strategies are in high demand and must be rationally based on biologic mechanisms of resistance. Particularly important is how to overcome a noninflamed tumor microenvironment and specific targets are currently under study from multiple mechanistic angles. For example, intratumoral STING and TLR agonists are being used to promote innate immunity, anti-CD40 agonists and CSF1R inhibitors to bridge innate and adaptive immunity, STAT3 inhibitors to inhibit immunosuppressive oncogene pathways, probiotics to reverse immunosuppression in the microbiome, and many more, often in combination with a PD-1

backbone, representing the next wave of treatment approaches in immuno-oncology (120). Optimizing clinical outcomes for special populations such as patients with mucosal and ocular melanomas, which are less responsive to ICIs, is also needed.

Tremendous scientific progress has been made in the past 10 years in understanding how to manipulate the immune system to improve outcomes in melanoma and has translated into unprecedented clinical success. Despite the major hurdles of resistance to ICIs, the challenges are defined and are being actively investigated. Ultimately, predictive biomarkers will need to personalize and guide treatment decisions for each individual patient with melanoma.

Disclosure of Potential Conflicts of Interest

S.A. Weiss is a consultant/advisory board member for Array BioPharma and Magellan Rx. J.D. Wolchok reports receiving commercial research grants from Bristol-Myers Squibb, MedImmune, and Genentech, speakers bureau honoraria from Esanex, holds ownership interest (including patents) in Potenza, Tizona Pharmaceuticals, Adaptive, Elucida, Imvaq, Beigene, Trieza, Seramatrix, and Linneaus, and is a consultant/advisory board member for Adaptive, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage, Astellas, Bayer, Beigene, Bristol-Myers Squibb, Celgene, Chugai, Elucida, Eli Lilly, F Star, Imvaq, Janssen, Kleo Pharma, Linneaus, Neon Therapeutics, Ono Pharma, Polaris Pharma, Polynoma, Psioxus, Puretech, Recepta, Sellas, Seramatrix, Surface Oncology, Syndax, Tizona, and Merck. M. Sznol holds stock options in Torque, Amphivena, Adaptive Biotechnologies, Intensity, and Actym, and is a consultant/advisory board member for Genentech/Roche, Bristol-Myers Squibb, AstraZeneca/MedImmune, Biodesix, Modulate Therapeutics, Newlink Genetics, Molecular Partners, Innate Pharma, AbbVie, Immunocore, Genmab, Almac, Hinge, Allakos, Anaeropharma, Array, Symphogen, Adaptimmune, Omnio, Pieris, Verseau, Torque, Lycera, Pfizer, Kyowa-Kirin, Pierre-Fabre, Merck, Theravance, Vaccinex, Janssen/Johnson & Johnson, Baxalta-Shire, Incyte, Lion Biotechnologies (Iovance), Agonox, Arbutus, Celldex, Inovio, Gritstone, Amphivena, Adaptive Biotechnologies, Intensity, and Actym. No other potential conflicts of interest were disclosed.

Acknowledgments

S. Weiss acknowledges NIH (NCI) research support from K12 CA215110.

Received December 26, 2018; revised February 21, 2019; accepted March 25, 2019; published first March 28, 2019.

References

- Guy GP Jr, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC. Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. *MMWR Morb Mortal Wkly Rep* 2015;64:591-6.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018;68:7-30.
- Brenner M, Hearing VJ. The protective role of melanin against UV damage in human skin. *Photochem Photobiol* 2008;84:539-49.
- Kawakami Y, Rosenberg SA. T-cell recognition of self peptides as tumor rejection antigens. *Immunol Res* 1996;15:179-90.
- Faramarzi S, Ghafouri-Fard S. Melanoma: a prototype of cancer-testis antigen-expressing malignancies. *Immunotherapy* 2017;9:1103-13.
- Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. *Cancer J Sci Am* 2000;6:S11-4.
- Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. *J Clin Oncol* 2001;19:2370-80.
- Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. *J Clin Oncol* 1996;14:7-17.
- Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, et al. Randomized selection design trial evaluating CD8+ enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. *J Clin Oncol* 2013;31:2152-9.
- Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myceloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. *J Clin Oncol* 2005;23:2346-57.
- Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan CQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin Cancer Res* 2011;17:4550-7.
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med* 2017;377:1345-56.

13. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, et al. 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. *J Clin Oncol* 36, 2018 (suppl; abstr 9516).
14. Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncol* 2018;19:1480–92.
15. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. *N Engl J Med* 2015;372:2521–32.
16. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med* 2015;373:23–34.
17. Tartari F, Santoni M, Burattini L, Mazzanti P, Onofri A, Berardi R. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges. *Cancer Treat Rev* 2016;48:20–4.
18. Andrews A. Treating with checkpoint inhibitors—figure \$1 million per patient. *Am Health Drug Benefits* 2015;8:9.
19. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. *J Immunol* 2014;192:5451–8.
20. Hurst JH. Cancer immunotherapy innovator James Allison receives the 2015 Lasker–DeBakey Clinical Medical Research Award. *J Clin Invest* 2015;125:3732–6.
21. Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). *J Immunother Cancer* 2018;6:39.
22. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol* 2013;13:227–42.
23. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* 2013;369:122–33.
24. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711–23.
25. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. *J Clin Oncol* 2013;31:616–22.
26. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res* 2009;15:7412–20.
27. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. *J Clin Oncol* 2015;33:3541–3.
28. Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. *J Clin Oncol* 2018;36:850–8.
29. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. *Clin Cancer Res* 2017;23:4242–50.
30. Champiat S, Derle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1/PD-L1. *Clin Cancer Res* 2017;23:1920–8.
31. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. *Clin Cancer Res* 2013;19:3936–43.
32. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekas S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. *Lancet Oncol* 2017;18:e143–e52.
33. Saada-Bouzd E, Defaucheux C, Karabajakian A, Coloma VP, Serois V, Paoletti X, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. *Ann Oncol* 2017;28:1605–11.
34. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. *J Clin Oncol* 2015;33:1889–94.
35. Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol* 2017;18:611–22.
36. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet* 2017;390:1853–62.
37. Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. *JAMA Oncol* 2018 Oct 25 [Epub ahead of print].
38. Long GV, Schachter J, Ribas A, Arance AM, Grob J-J, Mortier L, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. *J Clin Oncol* 36, 2018 (suppl; abstr 9503).
39. Hodi FS, Sznol M, Carvajal R, Lawrence D, Atkins M, et al. Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial AACR Annual Meeting 2016 [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16–20; New Orleans, LA. Philadelphia (PA): AACR; 2016. Abstract nr CT001.
40. Eroglu Z, Zaretsky JM, Hu-Lieskova S, Kim DW, Algazi A, Johnson DB, et al. High response rate to PD-1 blockade in desmoplastic melanomas. *Nature* 2018;553:347–50.
41. Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, et al. Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. *J Clin Oncol* 2019;37:52–60.
42. Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III Trials. *J Clin Oncol* 2017;35:3807–14.
43. Kirchberger MC, Hauschild A, Schuler G, Heinzerling L. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma. *Eur J Cancer* 2016;65:182–4.
44. Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. *Lancet Oncol* 2017;18:1202–10.
45. Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr., Lawrence DP, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. *Lancet Oncol* 2016;17:943–55.
46. Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forscher A, Gutzmer R, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. *Eur J Cancer* 2017;75:47–55.
47. Long GV, Robert C, Blank C, Ribas A, Mortier L, Schachter J, et al. Outcomes in patients treated with ipilimumab after pembrolizumab in KEYNOTE-006. *Eur J Cancer* 2017;72:S128–S129.
48. Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. *N Engl J Med* 2018;379:722–30.
49. Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncol* 2018;19:672–81.
50. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nat Med* 2018;24:1649–54.
51. D'Angelo SP, Larkin J, Sosman JA, Lebbe C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. *J Clin Oncol* 2017;35:226–35.

52. Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, et al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. *Immunotherapy* 2017;9:1323–30.
53. Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. *PLoS One* 2015;10:e0118564.
54. Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. *Cancer* 2016;122:3344–53.
55. Robertson AG, Shih J, You C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. *Cancer Cell* 2017;32:204–20.
56. Kaufman HL, Margolin K, Sullivan R. Management of metastatic melanoma in 2018. *JAMA Oncol* 2018;4:857–8.
57. Eggermont AM, Suciú S, Testori A, Santinami M, Kruit WH, Marsden J, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. *J Clin Oncol* 2012;30:3810–8.
58. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. *N Engl J Med* 2016;375:1845–55.
59. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. *N Engl J Med* 2017;377:1824–35.
60. Eggermont AM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. *N Engl J Med* 2018;378:1789–801.
61. Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. *J Clin Oncol* 2018;36:3441–49.
62. Ozao-Choy J, Lee DJ, Faries MB. Melanoma vaccines: mixed past, promising future. *Surg Clin North Am* 2014;94:1017–30.
63. Hellmann MD, Snyder A. Making it personal: neoantigen vaccines in metastatic melanoma. *Immunity* 2017;47:221–3.
64. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. *Nature* 2017;547:217–21.
65. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. *J Clin Oncol* 2015;33:2780–8.
66. Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTIM phase III clinical trial. *Ann Surg Oncol* 2016;23:4169–77.
67. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. *J Clin Oncol* 2018;36:1658–67.
68. Hu Q, Ye X, Qu X, Cui D, Zhang L, Xu Z, et al. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy. *Sci Rep* 2018;8:7675.
69. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. *J Clin Oncol* 2015;33:74–82.
70. Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, et al. Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors. *Clin Cancer Res* 2018;24:5552–61.
71. Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. *Clin Cancer Res* 2017;23:1929–36.
72. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. *J Clin Oncol* 2007;25:876–83.
73. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* 2014;515:568–71.
74. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443–54.
75. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. *Cell* 2018;175:998–1013.
76. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. *N Engl J Med* 2017;377:2500–1.
77. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. *Nature* 2013;500:415–21.
78. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N Engl J Med* 2014;371:2189–99.
79. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal *Bifidobacterium* promotes antitumor immunity and facilitates anti-PD-L1 efficacy. *Science* 2015;350:1084–9.
80. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science* 2018;359:104–8.
81. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. *Cell* 2016;165:35–44.
82. Siu LL, Ivy SP, Dixon EL, Gravell AE, Reeves SA, Rosner GL. Challenges and opportunities in adapting clinical trial design for immunotherapies. *Clin Cancer Res* 2017;23:4950–8.
83. Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, et al. Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials. *JAMA Oncol* 2017;3:1511–9.
84. Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, et al. Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the development of innovative cancer therapies. *Ann Oncol* 2018;29:2175–82.
85. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. *Cancer Res* 2012;72:917–27.
86. Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpınarlı A, et al. Restoring immune function of tumor-specific CD4⁺ T cells during recurrence of melanoma. *J Immunol* 2013;190:4899–909.
87. Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, et al. Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. *Front Immunol* 2018;9:385.
88. Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. *Immunol Rev* 2017;276:80–96.
89. Ascierto PA, Bono P, Bhatia S, Melero I, Nyakas MS, Svane IM, et al. LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. *Ann Oncol* 2017;28(suppl_5):v605–v49.
90. Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 inhibitors: from bench to bedside. *Cancer Res* 2017;77:6795–811.
91. Hamid O, Gajewski TF, Frankel AE, Bauer TM, Olszanski AJ, Luke JJ, et al. 1214OEpacadostat plus pembrolizumab in patients with advanced melanoma: phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037. *Ann Oncol* 2017;28(suppl_5):v428–v48.
92. Daud A, Saleh MN, Hu J, Bleeker JS, Riese MJ, Meier R, et al. Epacadostat plus nivolumab for advanced melanoma: updated phase 2 results of the ECHO-204 study. *J Clin Oncol* 36, 2018 (suppl; abstr 9511).
93. Long GV, Dummer R, Hamid O, Gajewski T, Caglevic C, Dalle S, et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301/KEYNOTE-252 study. *J Clin Oncol* 36, 2018 (suppl; abstr 108).
94. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. *Cancer Res* 2014;74:5057–69.

95. Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. *Adv Drug Deliv Rev* 2016;99:180–5.
96. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. *Cancer Sci* 2014;105:1–8.
97. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. *Clin Cancer Res* 2004;10:173–7.
98. Perry CJ, Munoz-Rojas AR, Meeth KM, Kellman LN, Amezcua RA, Thakral D, et al. Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. *J Exp Med* 2018;215: 877–93.
99. Makkouk A, Chester C, Kohrt HE. Rationale for anti-CD137 cancer immunotherapy. *Eur J Cancer* 2016;54:112–9.
100. Bartkowiak T, Curran MA. 4-1BB agonists: multi-potent potentiators of tumor immunity. *Front Oncol* 2015;5:117.
101. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. *PLoS One* 2011;6:e19499.
102. Chen S, Lee LF, Fisher TS, Jessen B, Elliott M, Evering W, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. *Cancer Immunol Res* 2015;3:149–60.
103. Sznol M, Hodi FS, Margolin K, McDermott DF, Ernstoff MS, Kirkwood JM, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). *J Clin Oncol* 26:15s, 2008 (suppl; abstr 3007).
104. Kocak E, Lute K, Chang X, May KF Jr., Exten KR, Zhang H, et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. *Cancer Res* 2006;66:7276–84.
105. Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. *Clin Cancer Res* 2016;22:680–90.
106. Melisi D, Frizziero M, Tamburrino A, Zanotto M, Carbone C, Piro G, et al. Toll-like receptor 9 agonists for cancer therapy. *Biomedicines* 2014;2: 211–28.
107. Diab A, Rahimian S, Haymaker CL, Bernatchez C, Andtbacka RHI, James M, et al. A phase 2 study to evaluate the safety and efficacy of intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma. *J Clin Oncol* 2018;36:9515.
108. Milhem MM, Zarour HM, Gabrail NY, Mauro DJ, Greenberg NM, Slichenmyer WJ, et al. Phase Ib trial of the CpG-A oligonucleotide CMP-001 combined with pembrolizumab (pembro) in patients with advanced melanoma. *J Clin Oncol* 2016;34:15s, (suppl; abstr TPS9593).
109. Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, et al. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th–3rd December 2016. *J Translat Med* 2017;15:236.
110. Sarnaik A, Kluger HM, Chesney JA, Sethuraman J, Veerapathran A, Simpson-Abelson M, et al. Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy. *J Clin Oncol* 35, 2017 (suppl; abstr 3045).
111. Forget M-A, Haymaker CL, Hess KR, Roszik J, Woodman SE, Fulbright OJ, et al. The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: an update from MD Anderson Cancer Center. *J Clin Oncol* 35:7s, 2017 (suppl; abstr 138).
112. Sarnaik A TS, Davar D, Kirkwood J, Kluger H, Lutzky J, et al. Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors [abstract]. In: Proceedings of the Society of Immunotherapy of Cancer Annual Meeting; 2018 November 9–11; Washington, DC. Milwaukee (WI): SITC; 2018.
113. Ping Y, Liu C, Zhang Y. T-cell receptor-engineered T cells for cancer treatment: current status and future directions. *Protein Cell* 2018;9:254–66.
114. Hermel DJ, Ott PA. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. *Cancer Metastasis Rev* 2017;36:43–50.
115. Ascierto PA, Ferrucci PF, Stephens R, Del Vecchio M, Atkinson V, Schmidt H, et al. KEYNOTE-002 part 3: phase 2 randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. *Ann Oncol* 2018; 29 (suppl_8):viii442–viii66.
116. Dummer R, Ramey E, Schindler S, Thurigen O, Levesque MP, Koelblinger P. MEK inhibition and immune responses in advanced melanoma. *Oncimmunology* 2017;6:e1335843.
117. Miller WH, Kim TM, Lee CB, Flaherty KT, Reddy S, Jamal R, et al. Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): updated safety and clinical activity. *J Clin Oncol* 35:15s, 2017 (suppl; abstr 3057).
118. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. *J Clin Oncol* 2018;36:1668–74.
119. Robert C, Long GV, Schachter J, Arance A, Grob JJ, Mortier L, et al. Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. *J Clin Oncol* 35:15s, 2017 (suppl; abstr 9504).
120. Gajewski TF. The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment. *Semin Oncol* 2015;42: 663–71.
121. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet* 2014;384:1109–17.
122. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncol* 2015;16:908–18.
123. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol* 2015;16: 375–84.
124. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med* 2015;372:320–30.
125. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *N Engl J Med* 2015;372:2006–17.